Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025

DelveInsight’s “Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025” report delivers in-depth information on over 20 companies and more than 22 pipeline drugs in the Relapsing-Remitting Multiple Sclerosis treatment landscape. It features Relapsing-Remitting Multiple Sclerosis pipeline drug profiles for clinical and nonclinical stage products. It also evaluates Relapsing-Remitting Multiple Sclerosis therapeutics by product type, development stage, administration route, and molecule type. Additionally, it emphasizes inactive pipeline products in this field.

Keep up with cutting-edge developments! Obtain DelveInsight’s thorough Relapsing-Remitting Multiple Sclerosis Pipeline Report to investigate novel therapies, prominent Relapsing-Remitting Multiple Sclerosis Companies, and upcoming Relapsing-Remitting Multiple Sclerosis treatment scenarios @ Relapsing-Remitting Multiple Sclerosis Pipeline Outlook Report

Key Insights from the Relapsing-Remitting Multiple Sclerosis Pipeline Report

In June 2025, Novartis Pharmaceuticals disclosed a study aimed at assessing whether relapsing-remitting MS patients without a relapse in the past year could gain advantages from transitioning to ofatumumab compared to continuing their existing treatment. The study will also examine if heightened serum neurofilament light (NfL) levels indicate greater benefits from switching to ofatumumab.
In June 2025, Celgene performed a study to assess the efficacy, safety, tolerability, drug concentrations, and effects of ozanimod versus fingolimod in children and teenagers with relapsing remitting multiple sclerosis (RRMS).
DelveInsight’s Relapsing-Remitting Multiple Sclerosis pipeline report portrays a dynamic arena with over 20 active contributors advancing more than 22 pipeline therapies for Relapsing-Remitting Multiple Sclerosis care.
Leading Relapsing-Remitting Multiple Sclerosis Companies include Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda, and others.
Promising Relapsing-Remitting Multiple Sclerosis Therapies encompass TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others.
Learn how the Relapsing-Remitting Multiple Sclerosis treatment approach is shifting. Review DelveInsight’s detailed Relapsing-Remitting Multiple Sclerosis Pipeline Analysis for insights into potential advancements @ Relapsing-Remitting Multiple Sclerosis Clinical Trials and Studies

Relapsing-Remitting Multiple Sclerosis Emerging Drugs Profile

IMU-838: Immunic AG
Vidofludimus calcium is an oral investigational small molecule being developed for persistent inflammatory and autoimmune conditions, presently in advanced clinical testing for multiple sclerosis (MS). Distinctively, vidofludimus calcium’s pioneering dual mechanism merges neuroprotective, anti-inflammatory, and antiviral properties to address MS's intricate pathology. As a targeted immune regulator, it stimulates the neuroprotective factor nuclear receptor-related 1 (Nurr1), yielding direct and indirect protective effects. Furthermore, vidofludimus calcium exerts anti-inflammatory and antiviral actions via selective blockade of the dihydroorotate dehydrogenase (DHODH) enzyme. The drug is currently in Phase III for Relapsing-Remitting Multiple Sclerosis treatment.

IMCY-0141: Imcyse SA
IMCY-0141 Imotope™ is engineered around MOG (Myelin Oligodendrocyte Glycoprotein) to arrest multiple sclerosis (MS) advancement by preventing the immune system from assaulting the central nervous system and halting harmful autoimmune reactions that erode the myelin sheath safeguarding nerves. IMCY-0141 has demonstrated encouraging outcomes in various MS preclinical models, eliciting an immune reaction that validates its intended mechanism and fostering a lasting memory response for sustained effects with infrequent administration. Moreover, initiating therapy promptly could enable patients to experience minimal disease interference. The drug is in Phase I/II development for Relapsing-Remitting Multiple Sclerosis.

ANK-700: Anokion SA
ANK-700 is an experimental treatment from Anokion for Relapsing-Remitting Multiple Sclerosis (RRMS). It utilizes a unique "inverse vaccine" strategy to retrain the immune system to identify certain myelin proteins as "self," thus averting autoimmune assaults on the central nervous system. This method aims to diminish neuroinflammation while upholding general immune capabilities. Anokion's technique leverages its proprietary immune tolerance platform, focusing on hepatic pathways to reinstate immune tolerance. This liver-directed antigen approach efficiently boosts antigen-specific regulatory T-cells in vivo, presenting therapeutic promise for diverse inflammatory disorders, including multiple sclerosis. ANK-700's groundbreaking mechanism and positive initial clinical findings establish it as a hopeful contender for forthcoming disease-modifying treatments in RRMS. The drug is in Phase I for Relapsing-Remitting Multiple Sclerosis.

The Relapsing-Remitting Multiple Sclerosis pipeline report provides insights into

• The report offers in-depth details on organizations creating therapies for Relapsing-Remitting Multiple Sclerosis, including the total therapies per company.

• It examines diverse therapeutic candidates divided into early, mid, and late development phases for Relapsing-Remitting Multiple Sclerosis management.

• Relapsing-Remitting Multiple Sclerosis Companies are engaged in focused therapeutics development, with active and inactive (dormant or terminated) initiatives.

• Relapsing-Remitting Multiple Sclerosis Drugs in progress, classified by development phase, delivery method, target receptor, monotherapy or combo therapy, unique action mechanisms, and molecular structure.

• Comprehensive review of partnerships (corporate-corporate and corporate-academic), licensing deals, and funding for advancing the Relapsing-Remitting Multiple Sclerosis market.

Obtain a thorough examination of recent breakthroughs in the Relapsing-Remitting Multiple Sclerosis pipeline. Review DelveInsight’s professional report now! @ Relapsing-Remitting Multiple Sclerosis Unmet Needs

Relapsing-Remitting Multiple Sclerosis Companies

Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others.

Relapsing Remitting multiple sclerosis pipeline report assesses pipeline drugs by Route of Administration. Products are grouped under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Relapsing-Remitting Multiple Sclerosis Products are classified by Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Acquire DelveInsight’s newest report for strategic perspectives on forthcoming Relapsing-Remitting Multiple Sclerosis Therapies and major Relapsing-Remitting Multiple Sclerosis Advancements @ Relapsing-Remitting Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives

Scope of the Relapsing-Remitting Multiple Sclerosis Pipeline Report

Coverage- Global
Relapsing-Remitting Multiple Sclerosis Companies- Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others.
Relapsing-Remitting Multiple Sclerosis Therapies- TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others.
Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which firms are spearheading progress in Relapsing-Remitting Multiple Sclerosis drug innovation? Discover in DelveInsight’s specialized Relapsing-Remitting Multiple Sclerosis Pipeline Report—secure it today! @ Relapsing-Remitting Multiple Sclerosis Emerging Drugs and Major Companies

Table of Contents

1. Introduction

2. Executive Summary

3. Relapsing-Remitting Multiple Sclerosis: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Relapsing-Remitting Multiple Sclerosis– DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. IMU-838: Immunic AG

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. Telitacicept: RemeGen

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. ANK700: Anokion

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Relapsing-Remitting Multiple Sclerosis Key Companies

21. Relapsing-Remitting Multiple Sclerosis Key Products

22. Relapsing-Remitting Multiple Sclerosis- Unmet Needs

23. Relapsing-Remitting Multiple Sclerosis- Market Drivers and Barriers

24. Relapsing-Remitting Multiple Sclerosis- Future Perspectives and Conclusion

25. Relapsing-Remitting Multiple Sclerosis Analyst Views

26. Relapsing-Remitting Multiple Sclerosis Key Companies

27. Appendix

About Us

DelveInsight is a premier healthcare market research and consulting firm supplying clients with superior market intelligence and analysis to aid strategic choices. With a group of seasoned industry professionals and extensive knowledge of life sciences and healthcare, we deliver bespoke research solutions and insights globally. Contact us for dependable, precise, and current intelligence to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com